Posted On: 02/23/2015 8:40:33 AM
Post# of 30034
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Download PDF
SAN FRANCISCO and GENEVA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that its abstract titled, "The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.
The poster will highlight the positive data analysis of whole blood samples from 140 subjects (71 Alzheimer's disease and 69 age matched controls) using the company's LymPro Test blood-based assay for Alzheimer's disease (AD). The LymPro Test measures lymphocyte proliferation in response to a mitogenic stimulus and quantifies the extent to which lymphocytes have entered the cell division cycle. Cell cycle dysregulation in neurons is a key pathology in AD, that results in neuronal death and cognitive decline. In the LymPro test, lymphocyte measurements are used as a surrogate for this neuronal cell dysfunction. The analysis demonstrates that, in combination with standard of care clinical measurements, LymPro can give physicians greater confidence that an Alzheimer's diagnosis is truly accurate.
"We are very pleased to have this confirmatory LymPro abstract accepted for a poster session at one of the premiere scientific congresses focused on neurological disorders," said Gerald E. Commissiong, President & CEO of Amarantus BioSciences Holdings, Inc. "We believe the LymPro Test is an important leading Alzheimer's biomarker assay and is a key diagnostic asset for advancing robust therapeutic clinical studies in Alzheimer's disease. This conference will provide important exposure as we continue building a significant customer base for blood-based biomarker services in Alzheimer's disease, with the ultimate shared goal of improving the current standard of care used to treat AD."
The poster data to be presented at AD/PD 2015 by Louis Kirby, Corporate Advisor and Medical Director of Amarantus Diagnostics, confirms the consistent and accurate ability of the LymPro Test to distinguish univariate and multivariate combination indicators of lymphocyte proliferation AD biomarkers from controls. Additionally, the analysis corroborates two previous peer-reviewed publications in which data from the Company's recently completed LP-002 clinical study established the LymPro Test as an advantageous diagnostic that can serve as the first step in a multistep diagnostic process for early identification of Alzheimer's disease.
Download PDF
SAN FRANCISCO and GENEVA, Feb. 23, 2015 (GLOBE NEWSWIRE) -- Amarantus BioSciences Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products with the potential for orphan drug designation in the areas of neurology, psychiatry, ophthalmology and regenerative medicine, announced that its abstract titled, "The LymPro® Assay: A Biomarker For Alzheimer's Disease Using Blood Samples From Clinically Diagnosed Alzheimer's Disease And Cognitively Intact Subjects," was accepted for poster presentation at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PDTM 2015) being held March 18-22, 2015, in Nice, France.
The poster will highlight the positive data analysis of whole blood samples from 140 subjects (71 Alzheimer's disease and 69 age matched controls) using the company's LymPro Test blood-based assay for Alzheimer's disease (AD). The LymPro Test measures lymphocyte proliferation in response to a mitogenic stimulus and quantifies the extent to which lymphocytes have entered the cell division cycle. Cell cycle dysregulation in neurons is a key pathology in AD, that results in neuronal death and cognitive decline. In the LymPro test, lymphocyte measurements are used as a surrogate for this neuronal cell dysfunction. The analysis demonstrates that, in combination with standard of care clinical measurements, LymPro can give physicians greater confidence that an Alzheimer's diagnosis is truly accurate.
"We are very pleased to have this confirmatory LymPro abstract accepted for a poster session at one of the premiere scientific congresses focused on neurological disorders," said Gerald E. Commissiong, President & CEO of Amarantus BioSciences Holdings, Inc. "We believe the LymPro Test is an important leading Alzheimer's biomarker assay and is a key diagnostic asset for advancing robust therapeutic clinical studies in Alzheimer's disease. This conference will provide important exposure as we continue building a significant customer base for blood-based biomarker services in Alzheimer's disease, with the ultimate shared goal of improving the current standard of care used to treat AD."
The poster data to be presented at AD/PD 2015 by Louis Kirby, Corporate Advisor and Medical Director of Amarantus Diagnostics, confirms the consistent and accurate ability of the LymPro Test to distinguish univariate and multivariate combination indicators of lymphocyte proliferation AD biomarkers from controls. Additionally, the analysis corroborates two previous peer-reviewed publications in which data from the Company's recently completed LP-002 clinical study established the LymPro Test as an advantageous diagnostic that can serve as the first step in a multistep diagnostic process for early identification of Alzheimer's disease.
(0)
(0)Scroll down for more posts ▼
